Take-up Rate of Human Papillomavirus Vaccines by Adults

Debated in Parliament on 7 Nov 2023.

Summary written by AI (learn more)

Gerald Giam asked for past five years' HPV vaccine take-up rates among adults aged 18–64, split by bivalent, quadrivalent, and 9-valent vaccines, and whether the Ministry plans to include the 9-valent vaccine in the National Adult Immunisation Schedule with subsidies and MediSave use for ages 27–64.
Ong Ye Kung stated that HPV vaccination is nationally recommended for females aged nine to 26, with no vaccine approved for those over 45, and more than 90% of Secondary 1 female students were vaccinated in 2022.
Ong Ye Kung noted the Ministry lacks data on HPV vaccination by vaccine type across all ages and said the 9-valent vaccine is not cost-effective compared to the bivalent vaccine, so it is not included in national immunisation schedules or eligible for subsidies or MediSave claims.

Questions identified by AI (learn more)

Full Transcript

Gerald Giam Yean Song

Mr Gerald Giam Yean Song asked the Minister for Health (a) in each of the past five years, what was the take-up rate of human papillomavirus (HPV) (i) bivalent (ii) quadrivalent and (iii) 9-valent vaccines by adults aged between 18 and 64; and (b) whether the Ministry plans to (i) include HPV 9-valent vaccines under the National Adult Immunisation Schedule and (ii) provide subsidies and allow the use of MediSave for HPV 9-valent vaccines for those aged between 27 and 64 years.

Ong Ye Kung

The human papillomavirus (HPV) vaccination is nationally recommended for females aged nine to 26 years for prevention of cervical cancer in females. No HPV vaccine has been approved by the Health Sciences Authority for use in persons older than 45 years.

The Ministry of Health does not have data on HPV vaccination by vaccine type across all ages. However, as HPV vaccination is offered to all Secondary 1 female students, our records show that in 2022, more than 90% of Secondary 1 female students have received the vaccine.

The HPV 9-valent vaccine is currently not cost-effective when compared to the bivalent HPV vaccine, based on the pricing of the manufacturer. Hence, it is not included under the national immunisation schedules and is not eligible for subsidy or MediSave claims.

Summary written by AI (learn more)

Gerald Giam asked for past five years' HPV vaccine take-up rates among adults aged 18–64, split by bivalent, quadrivalent, and 9-valent vaccines, and whether the Ministry plans to include the 9-valent vaccine in the National Adult Immunisation Schedule with subsidies and MediSave use for ages 27–64.
Ong Ye Kung stated that HPV vaccination is nationally recommended for females aged nine to 26, with no vaccine approved for those over 45, and more than 90% of Secondary 1 female students were vaccinated in 2022.
Ong Ye Kung noted the Ministry lacks data on HPV vaccination by vaccine type across all ages and said the 9-valent vaccine is not cost-effective compared to the bivalent vaccine, so it is not included in national immunisation schedules or eligible for subsidies or MediSave claims.

Questions identified by AI (learn more)

Take-up Rate of Human Papillomavirus Vaccines by Adults | PAPERCUTS

Take-up Rate of Human Papillomavirus Vaccines by Adults

Debated in Parliament on 7 Nov 2023.

Summary written by AI (learn more)

Gerald Giam asked for past five years' HPV vaccine take-up rates among adults aged 18–64, split by bivalent, quadrivalent, and 9-valent vaccines, and whether the Ministry plans to include the 9-valent vaccine in the National Adult Immunisation Schedule with subsidies and MediSave use for ages 27–64.
Ong Ye Kung stated that HPV vaccination is nationally recommended for females aged nine to 26, with no vaccine approved for those over 45, and more than 90% of Secondary 1 female students were vaccinated in 2022.
Ong Ye Kung noted the Ministry lacks data on HPV vaccination by vaccine type across all ages and said the 9-valent vaccine is not cost-effective compared to the bivalent vaccine, so it is not included in national immunisation schedules or eligible for subsidies or MediSave claims.

Questions identified by AI (learn more)

Full Transcript

Gerald Giam Yean Song

Ong Ye Kung

Summary written by AI (learn more)

Gerald Giam asked for past five years' HPV vaccine take-up rates among adults aged 18–64, split by bivalent, quadrivalent, and 9-valent vaccines, and whether the Ministry plans to include the 9-valent vaccine in the National Adult Immunisation Schedule with subsidies and MediSave use for ages 27–64.
Ong Ye Kung stated that HPV vaccination is nationally recommended for females aged nine to 26, with no vaccine approved for those over 45, and more than 90% of Secondary 1 female students were vaccinated in 2022.
Ong Ye Kung noted the Ministry lacks data on HPV vaccination by vaccine type across all ages and said the 9-valent vaccine is not cost-effective compared to the bivalent vaccine, so it is not included in national immunisation schedules or eligible for subsidies or MediSave claims.

Questions identified by AI (learn more)

Take-up Rate of Human Papillomavirus Vaccines by Adults

Summary

Questions Identified

Full Transcript

Gerald Giam Yean Song

Ong Ye Kung

Summary

Questions Identified

Take-up Rate of Human Papillomavirus Vaccines by Adults

Summary

Questions Identified

Full Transcript

Gerald Giam Yean Song

Ong Ye Kung

Summary

Questions Identified